Claims for Patent: 7,632,858

Summary for Patent: 7,632,858

Title:	Open chain prolyl urea-related modulators of androgen receptor function
Abstract:	The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, X, Y, Z and G are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
Inventor(s):	Hamann; Lawrence G. (Cherry Hill, NJ), Augeri; David J. (Princeton, NJ), Manfredi; Mark C. (Hamilton, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	10/712,456
Patent Claims:	1. A compound of formula I ##STR00026## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is selected from the group consisting of alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and CH.sub.2OR.sub.4; R.sub.2 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocycle or substituted heterocycle, heteroaryl or substituted heteroaryl and CH.sub.2OR.sub.4; R.sub.3 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, CH.sub.2OR.sub.4, OR.sub.2, SR.sub.2, halo, NHR.sub.2, NHCOR.sub.4, and NHCONR.sub.4R.sub.4'; R.sub.4 and R.sub.4' for each occurrence are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo and heteroaryl or substituted heteroaryl; G is selected from among: ##STR00027## wherein R.sub.8 is CN; R.sub.9, R.sub.10, and R.sub.11 are each independently selected from the group consisting of hydrogen (H), NO.sub.2, CN, CF.sub.3, OR.sub.4, CO.sub.2R.sub.4, NR.sub.4R.sub.4', CONR.sub.4R.sub.4', CH.sub.2OR.sub.4, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl; A to F each independently is selected from among N and CR.sub.1; J, K, L, P, and Q each independently is selected from among NR.sub.12, O, S, SO, SO.sub.2 or CR.sub.12R.sub.12'; R.sub.12 and R.sub.12' in each functional group are each independently selected from a bond or R.sub.1; m is an integer of 0 or 1; X is a linking group selected from the group consisting of NR.sub.4 and CHR.sub.4; Y is selected from the group consisting of O, NR.sub.4, NOR.sub.4, S and CH.sub.2; and Z is --O--, or NR.sub.4; with the following provisos: (a) when Y is NOR.sub.4, R.sub.4 is not hydrogen; (b) when R.sub.1 is methyl, X is NH, and Y is O or S, then Z is not O; (c) when (i) R.sub.1 is methyl, (ii) X is NH, (iii) Y is NR.sub.4, (iv) R.sub.4 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl, and (v) G has the following structure: ##STR00028## wherein: R.sub.13 is selected from the group consisting of hydrogen, cyano (--CN), nitro (--NO.sub.2), halo, heterocyclo, OR.sub.14, CO.sub.2R.sub.15, CONHR.sub.15, COR.sub.15, S(O).sub.pR.sub.15, SO.sub.2NR.sub.15NR.sub.15', NHCOR.sub.15 and NHSO.sub.2R.sub.15; R.sub.14 in each functional group is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.15; R.sub.15 and R.sub.15' in each functional group are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl and --CN; AA and BB each independently is selected from the group consisting of hydrogen, halo, cyano (--CN), nitro (--NO.sub.2), alkyl or substituted alkyl and OR.sub.14; and p is an integer from 0 to 2, then Z is not O. 2. The compound of claim 1, or a pharmaceutically acceptable salt of claim 1, wherein: R.sub.1 is alkyl; R.sub.2 is hydrogen or alkyl; R.sub.3 is hydroxyl; X is NR.sub.4; Y is O; and Z is O. 3. A pharmaceutical composition, comprising: a compound or salt of claim 1; and a pharmaceutically acceptable carrier therefor. 4. The pharmaceutical composition of claim 3, further comprising a growth promoting agent. 5. A pharmaceutical composition, comprising: a compound of claim 1, or a pharmaceutically acceptable salt of claim 1; and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics. 6. A method for treating prostate cancer, comprising: administering to a mammalian species in need of treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of claim 1. 7. A compound selected from the group consisting of 1-(4-Cyano-2-ethyl-3-(trifluoromethyl)phenyl-1-carbamoyl)-3-hydroxy-pyrro- lidine-2-carboxylic acid or a pharmaceutically acceptable salt thereof; 1-(4-Cyanonaphthalen-1-ylcarbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt thereof; 1-(5-Chloro-6-cyano-pyridin-3-ylcarbamoyl)-3-hydroxypyrrolidine-2-carboxy- lic acid methyl ester or a pharmaceutically acceptable salt thereof; and 1-[2-(4-Cyanonaphthalen-1-yl)acetyl]-3-hydroxypyrrolidine-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition, comprising: a compound of claim 7, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier therefor. 9. The pharmaceutical composition of claim 8, further comprising a growth promoting agent. 10. A pharmaceutical composition, comprising: a compound of claim 7, or a pharmaceutically acceptable salt thereof; and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics. 11. A method for treating prostate cancer, comprising: administering to a mammalian species in need of treatment an effective amount of a compound of claim 7 or a pharmaceutically acceptable salt thereof. 12. A compound of formula I ##STR00029## or a pharmaceutically acceptable salt thereof, wherein: R.sub.1 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and CH.sub.2OR.sub.4; R.sub.2 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, heteroaryl or substituted heteroaryl and CH.sub.2OR.sub.4; R.sub.3 is selected from the group consisting of alkyl or substituted alkyl, and CH.sub.2R.sub.4; R.sub.4 and R.sub.4' for each occurrence are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo and heteroaryl or substituted heteroaryl; G is selected from the group consisting of: ##STR00030## wherein: R.sub.8 is CN; R.sub.9, R.sub.10, and R.sub.11 are each independently selected from the group consisting of hydrogen (H), NO.sub.2, CN, CF.sub.3, OR.sub.4, CO.sub.2R.sub.4, NR.sub.4R.sub.4', CONR.sub.4R.sub.4', CH.sub.2OR.sub.4, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl; A to F each independently is selected from among N and CR.sub.1; J, K, L, P, and Q each independently is selected from among NR.sub.12, O, S, SO, SO.sub.2 or CR.sub.12R.sub.12'; R.sub.12 and R.sub.12' in each functional group are each independently selected from a bond or R.sub.1; m is an integer of 0 or 1; X is a linking group selected from the group consisting of NR.sub.4 and CHR.sub.4; Y is selected from the group consisting of O, NR.sub.4, NOR.sub.4, S and CH.sub.2; and Z is --O--, or NR.sub.4; with the following provisos: (a) when Y is NOR.sub.4, R.sub.4 is not hydrogen; (b) when R.sub.1 is methyl, X is NH, and Y is O or S, then Z is not O; (c) when (i) R.sub.1 is methyl, (ii) X is NH, (iii) Y is NR.sub.4, (iv) R.sub.4 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl, and (v) G has the following structure: ##STR00031## wherein: R.sub.13 is selected from the group consisting of hydrogen, cyano (--CN), nitro (--NO.sub.2), halo, heterocyclo, OR.sub.14, CO.sub.2R.sub.15, CONHR.sub.15, COR.sub.15, S(O).sub.pR.sub.15, SO.sub.2NR.sub.15NR.sub.15', NHCOR.sub.15 and NHSO.sub.2R.sub.15; R.sub.14 in each functional group independently is selected from the group consisting of hydrogen, alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.15; R.sub.15 and R.sub.15' in each functional group are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl and CN; AA and BB each independently is selected from the group consisting of hydrogen, halo, cyano (--CN), nitro (--NO.sub.2), alkyl or substituted alkyl and OR.sub.14; and p is an integer from 0 to 2, then Z is not O. 13. A pharmaceutical composition, comprising: a compound of claim 12, or a pharmaceutically acceptable salt of claim 12; and a pharmaceutically acceptable carrier therefor. 14. The pharmaceutical composition of claim 13, further comprising a growth promoting agent. 15. A pharmaceutical composition, comprising: a compound of claim 12, or a pharmaceutically acceptable salt of claim 12; and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics. 16. A method for treating prostate cancer, comprising: administering to a mammalian species in need of treatment an effective amount of a compound of claim 12 or a pharmaceutically acceptable salt of claim 12.

Details for Patent 7,632,858

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-11-15